

# Almirall e-MS Experts Summit Season 2020

- **Due to the COVID-19 crisis, the 8<sup>th</sup> MS Experts Summit Season 2020 will be held online for first time.**
- **Eighteen multiple sclerosis (MS) experts and researchers from all over Europe will discuss the latest advances in MS over 7 weeks starting in June.**
- **The inaugural session will discuss the impact of COVID-19 on MS, addressing COVID-19 de-confinement and possible new spikes and vaccination advice for MS clinicians.**

Almirall, S.A. (ALM) announces the 8<sup>th</sup> edition of the MS Experts Summit continuous medical learning project, which will take place from June 10 to September 16, chaired by Prof. Christoph Kleinschmitz (Essen, Germany). The year edition will be conducted online for first time, with sessions streamed on seven days throughout June, July and September.

Under the title “*People with MS: 360° evidence-based daily management*,” several experts and researchers working in different areas of multiple sclerosis have prepared interesting lectures describing the latest advances across multiple aspects of managing patients who suffer from MS.

The inaugural session will address the issue of MS patients suffering from COVID-19, tackling their present needs as well as future vaccination requirements.

The Almirall e-MS Experts Summit will include two sessions on the use of cannabinoids in MS. Researchers will present the therapeutic benefits of phytocannabinoids from a scientific point of view, discussing the available evidence supporting the therapeutic effects of cannabinoids and describing the evidence-based approach for the use of medicinal cannabinoids.

*“We are delighted to once again provide our wholehearted support for this special edition of the MS Experts Summit, on this, the first time it is to be presented online. Although attendees will not participate live given the present circumstances, we expect the quality of the updated research presented by 18 eminent experts in MS to be consistent with our past events with interesting Q&A sessions following the presentations”*, remarked Carlos Vila, Global Medical Lead, Almirall.

Among other topics, the experts will address the similarities and differences in local guidance in various EU countries; recommendations from ECTRIMS and NICE in the UK concerning MS treatments, and methods for the improved diagnosis and tracking of MS spasticity-related symptoms.

Parallel country-specific sessions will tackle MS-related issues in the EU.

New technologies and digitalization are naturally an important part of the program of this digital summit. Several experts will discuss how digital technology can help in providing holistic patient care. This session called *How can digital technology help provide holistic patient care?*, will also address emerging digital technologies which may help physicians manage their patients and current trends in digital innovation in MS.

The e-MS Experts Summit will offer attending EU MS healthcare professionals the opportunity to advance their knowledge of the impact of MS symptoms on patients' daily activities as well as their quality of life.

## About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better. We support healthcare professionals in their continuous improvements, providing our innovative solutions where they are needed.

The company was founded more than 75 years ago and has its headquarters in Barcelona. It is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key source of value creation for society thanks to its commitment to its principal shareholders and its decision to help others by understanding their challenges and using science to provide solutions for real life. Total Revenues in 2019 were more than 900 million euros. Almirall has c. 1,800 employees.

For more information visit <https://www.almirall.com/>

## Corporate Communications contact:

Almirall

Noel Ortiz

[noel.ortiz@almirall.com](mailto:noel.ortiz@almirall.com)

Teléfono: (+34) 93 291 30 00

## Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate Communication [click here](#)

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: [dpo.global@almirall.com](mailto:dpo.global@almirall.com). PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.